查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593905

淋巴瘤药物市场：按治疗方法、最终用户划分 - 2025-2030 年全球预测

Lymphoma Therapeutics Market by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), End User (Ambulatory Surgical Centers, Clinics, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年淋巴瘤治疗市值为92.3亿美元，预计2024年将达105亿美元，复合年增长率为14.18%，预计2030年将达233.7亿美元。

淋巴瘤药物是指用于治疗淋巴瘤（一种发生在淋巴系统中的癌症）并增加治癒机会的治疗技术。这个市场包括化疗和放射线治疗等传统治疗方法，以及免疫疗法、标靶治疗和骨髓移植等先进方法。随着全球淋巴瘤盛行率的不断增加，对有效治疗药物的需求至关重要。这些治疗方法适用于各种类型的淋巴瘤，包括何杰金氏病和非何杰金氏病，最终用户包括医院、专门的癌症治疗中心和研究机构。市场成长主要受到淋巴瘤盛行率上升、生技药品进步以及政府对癌症研究经费增加的影响。新药疗法的开发和核准也是一个重大机会。製药公司正在积极投资研发，以发现 CAR T 细胞疗法等创新疗法，这些疗法正在显示出有希望的结果。然而，高昂的治疗成本、严格的监管要求以及与当前治疗方法相关的副作用等挑战限制了市场的成长。为了利用不断增长的机会，公司可以专注于个人化医疗和伴同性诊断，预计这将彻底改变淋巴瘤的治疗。与学术机构合作进行突破性研究并透过策略伙伴关係关係扩大新兴市场的进入可以进一步提高市场占有率。市场竞争激烈，各大公司都在积极寻求提高其药物的功效和安全性。对生物标的治疗的投资以及在药物发现中使用人工智慧被认为是创新的理想领域。此外，解决现有的挑战（例如获得治疗和优化药物输送系统）可以提高竞争力并推动可持续的业务成长。

主要市场统计
基准年[2023] 92.3亿美元
预测年份 [2024] 105亿美元
预测年份 [2030] 233.7亿美元
复合年增长率（%） 14.18%

市场动态：快速发展的淋巴瘤药物市场的关键市场洞察

供需的动态交互作用正在改变淋巴瘤药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 不同类型癌症的盛行率上升
    • 免疫查核点抑制剂和 Keytruda 等高级产品的采用率增加
    • 最近核准了多种新型疗法
  • 市场限制因素
    • 治疗费用上涨
  • 市场机会
    • 加强共同促销和商业化
    • 扩大研发业务
  • 市场挑战
    • 药品专利到期

波特的五力战略工具驾驭淋巴瘤药物市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解淋巴瘤药物市场的外部影响

外部宏观环境因素在塑造淋巴瘤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解淋巴瘤治疗药物市场的竞争状况

对淋巴瘤治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位基质淋巴瘤治疗市场供应商的绩效评估

FPNV定位矩阵是评估淋巴瘤治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划淋巴瘤治疗药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对淋巴瘤治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 各种癌症的发生率上升
      • 免疫查核点抑制剂和 Keytruda 等高级产品的采用率增加
      • 最近核准了几种新治疗方法
    • 抑制因素
      • 治疗费用上涨
    • 机会
      • 扩大共同促销和推销
      • 研究和开发活动显着成长
    • 任务
      • 药品专利到期
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗分類的淋巴瘤药物市场

  • 化疗
  • 免疫疗法
    • 嵌合体抗原受体T细胞疗法
    • 免疫查核点抑制剂
    • 单株抗体
  • 放射治疗
  • 干细胞或骨髓移植
  • 外科手术
  • 标靶治疗

第七章淋巴瘤治疗药物市场：依最终使用者分类

  • 门诊手术中心
  • 诊所
  • 医院

第八章美洲淋巴瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区淋巴瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲淋巴瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Accredo Health, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Seagen Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4342CA326620

The Lymphoma Therapeutics Market was valued at USD 9.23 billion in 2023, expected to reach USD 10.50 billion in 2024, and is projected to grow at a CAGR of 14.18%, to USD 23.37 billion by 2030.

Lymphoma therapeutics refers to the treatment methodologies applied to manage and potentially cure lymphoma, which is a type of cancer that originates in the lymphatic system. The scope of this market includes not only conventional therapies such as chemotherapy and radiation but also advanced approaches like immunotherapy, targeted therapy, and bone marrow transplantation. With an increasing global incidence of lymphoma, the necessity of effective therapeutics is paramount. Applications of these therapies span across various types of lymphoma, including Hodgkin and Non-Hodgkin varieties, with end-users comprising hospitals, specialized cancer treatment centers, and research facilities. Market growth is primarily influenced by the rising prevalence of lymphoma, advancements in biologics, and increased government funding for cancer research. The development and approval of novel drug therapies also present significant opportunities. Pharmaceutical companies are actively investing in R&D to discover innovative treatments, such as CAR T-cell therapy, which have shown promising outcomes. However, challenges such as high treatment costs, stringent regulatory requirements, and adverse side effects associated with current therapies pose limitations to market growth. To leverage the growing opportunities, companies can focus on personalized medicine and companion diagnostics, which are predicted to revolutionize lymphoma treatment. Collaboration with academic institutions for breakthrough research and expanding access in emerging markets through strategic partnerships can further enhance market presence. The market's nature is highly competitive, with major players actively seeking advancement in drug efficacy and safety profiles. Investing in biologically targeted therapies and leveraging artificial intelligence for drug discovery are considered the best areas for innovation. Furthermore, addressing existing challenges such as treatment accessibility and optimizing drug delivery systems can provide a competitive edge and foster sustainable business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 9.23 billion
Estimated Year [2024] USD 10.50 billion
Forecast Year [2030] USD 23.37 billion
CAGR (%) 14.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lymphoma Therapeutics Market

The Lymphoma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of different types of cancer
    • Increasing adoption of premium products such as immune checkpoint inhibitors and Keytruda
    • Recent approval of several novel therapies
  • Market Restraints
    • High cost of therapies
  • Market Opportunities
    • Increasing co-promotion and commercialization
    • Extensive growth in R&D practices
  • Market Challenges
    • Patent expiry of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Lymphoma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lymphoma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lymphoma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lymphoma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lymphoma Therapeutics Market

A detailed market share analysis in the Lymphoma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lymphoma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lymphoma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lymphoma Therapeutics Market

A strategic analysis of the Lymphoma Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lymphoma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Accredo Health, Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Lymphoma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell or Bone Marrow Transplantation, Surgery, and Targeted Therapy. The Immunotherapy is further studied across Chimeric Antigen Receptor T-Cell Therapy, Immune Checkpoint Inhibitors, and Monoclonal Antibodies.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of different types of cancer
      • 5.1.1.2. Increasing adoption of premium products such as immune checkpoint inhibitors and Keytruda
      • 5.1.1.3. Recent approval of several novel therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing co-promotion and commercialization
      • 5.1.3.2. Extensive growth in R&D practices
    • 5.1.4. Challenges
      • 5.1.4.1. Patent expiry of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lymphoma Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
    • 6.3.1. Chimeric Antigen Receptor T-Cell Therapy
    • 6.3.2. Immune Checkpoint Inhibitors
    • 6.3.3. Monoclonal Antibodies
  • 6.4. Radiation Therapy
  • 6.5. Stem Cell or Bone Marrow Transplantation
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Lymphoma Therapeutics Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Clinics
  • 7.4. Hospitals

8. Americas Lymphoma Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Lymphoma Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Lymphoma Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accredo Health, Inc.
  • 2. Amgen Inc.
  • 3. Bristol-Myers Squibb Company
  • 4. Eli Lilly and Company
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Gilead Sciences, Inc.
  • 7. GlaxoSmithKline PLC
  • 8. Johnson & Johnson Services, Inc.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Seagen Inc.
  • 13. Spectrum Pharmaceuticals, Inc.
  • 14. Takeda Pharmaceutical Company
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. LYMPHOMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LYMPHOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. LYMPHOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. LYMPHOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LYMPHOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LYMPHOMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY STEM CELL OR BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LYMPHOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM LYMPHOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. LYMPHOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. LYMPHOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023